Press Releases

Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test

Epic Sciences, Inc., ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI)…

Epic Sciences Announces Series B Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced today that it has completed a $13 million Series B equity financing. This financing includes new investors Domain Associates, Roche Venture…

Epic Sciences Announces Six Pharma Circulating Tumor Cell Collaborations

San Diego, CA - August 15, 2012 -- Epic Sciences, Inc. ("Epic"), a privately held cancer diagnostics company, announced today that it has established collaborations with six pharmaceutical partners employing Epic's proprietary Circulating Tumor Cell…